Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986189 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-986189 | EXPERIMENTAL | Specified Dose on Specified Day |
| Placebo | PLACEBO_COMPARATOR | Specified Dose on Specified Day |
| Name | Type | Description |
|---|---|---|
| BMS-986189 | DRUG | - |
| Placebo | OTHER | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy, males and females, 18 to 55 years of age, inclusive * Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive * Women of childbearing potential (WOCBP) must have nega...
BMS-986189 is an investigational small molecule being developed for severe sepsis, a life-threatening condition caused by an overwhelming immune response to infection. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-986189 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. The company's stock is traded under the ticker symbol BMY on the New York Stock Exchange.
BMS-986189 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval and is not yet available for clinical use outside of clinical trials.
BMS-986189 has one completed Phase 1 clinical trial, identified as NCT02739373. This study evaluated the pharmacokinetics, safety, tolerability, and pharmacodynamics of BMS-986189 in healthy subjects in the United States, with a total enrollment of 76 participants.
No, BMS-986189 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial focused on healthy subjects to assess safety and pharmacokinetics, and further clinical development would be required before any regulatory approval could be considered.